Abstract
EGFR mutation testing in non-small cell lung cancer (NSCLC) is a novel and important molecular pathological diagnostic assay that is predictive of response to anti-epidermal growth factor receptor (EGFR) therapy. A comprehensive compilation of a large number of EGFR mutation analyses of the German Panel for Mutation Analyses in NSCLC demonstrates (a) a higher than previously reported mutation frequency outside the conventionally tested exons 19 and 21 and (b) an overall superiority of sequencing based assays over mutation-specific PCR. The implications for future diagnostic EGFR mutation testing are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
Marchetti A, Felicioni L, Buttitta F, Tsao MS, Kamel-Reid S, Shepherd FA (2006) Assessing EGFR mutations. N Engl J Med 354:526–528
Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–1681
Somatic Mutations in Epidermal Growth Factor Receptor DataBase (2008) Department of Molecular Pathology and Translational Oncology at Metropolitan Hospital, Athens, Greece. www.somaticmutations-egfr.info/index.html
Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429–431
Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967
Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15:5267–5273
Conflict of interest
Round-robin testing of the panel institutes was supported by Astra Zeneca.
Author information
Authors and Affiliations
Corresponding author
Additional information
R. Penzel, C. Sers, Y. Chen, U. Lehmann-Mühlenhoff, S. Merkelbach-Bruse, A. Jung, T. Kirchner, R. Büttner, H.H. Kreipe, I. Petersen, M. Dietel, P. Schirmacher are members of the German Panel for Mutation Testing in NSCLC.
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM. 1
(PDF 9.08 kb)
Rights and permissions
About this article
Cite this article
Penzel, R., Sers, C., Chen, Y. et al. EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch 458, 95–98 (2011). https://doi.org/10.1007/s00428-010-1000-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-010-1000-y